Outlook Therapeutics Reports Financial Results for Second Qu

15.05.2023 - Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD)Pre-launch commercial activities ...

Related Keywords

United States , Russia , Japan , Ukraine , United Kingdom , China , Jenene Thomas , Harriet Ullman , Fujifilm , Outlook Therapeutics Inc , Lavoie Health Science , Alliance Healthcare , Amerisourcebergen , Committee For Medicinal Products Human Use , Aji Bio Pharma Services , Exchange Commission , Upcoming Anticipated , Planning Underway , Support Potential Approval , First Ophthalmic Formulation , Outlook Therapeutics , Pre Launch Preparations Proceeding , Marketing Authorization Application , Medicinal Products , Human Use , Syntone Biopharma , Special Protocol Assessments , Fiscal Second Quarter Ended March , Outlook Therapeutic , Annual Report ,